IDEXX Laboratories’ ProCyte Dx Hematology Analyzer Now Available in Europe [Trade]

Early customer feedback indicates that the analyzer exceeds customers’ expectations

WESTBROOK, Maine, January 14, 2011—IDEXX Laboratories, Inc. announces that the ProCyte Dx Hematology Analyzer is now available in Europe. Launched in the U.S. and Canada in June 2010, it has been enthusiastically adopted by veterinary clinics, with several hundred now installed in North America. The Company plans to introduce the analyzer in Asia later this year. This newest addition to the IDEXX VetLab diagnostic suite of in-house veterinary analyzers is surpassing customers' expectations for performance and usability, as well as for available training and support.

“The ProCyte Dx analyzer has gone through a unique and thorough development and evaluation process1 involving multiple university experts, laboratories and many veterinary practices, as well as IDEXX’s own staff of outstanding scientists,” said Alan Rebar, DVM, PhD, DACVP, and Professor of Veterinary Clinical Pathology at the Purdue University School of Veterinary Medicine. “The result is an in-house hematology analyzer that provides the veterinarian in the field with complete, precise hematology (CBC) data from a whole blood sample in just two minutes. Its results compare favorably to results produced with the most advanced hematology analyzers in use in veterinary academic and reference laboratories around the world today.”2

The ProCyte Dx analyzer meets the needs of universities, specialty and referral practices, as well as both large and small practices, including the general practitioner, allowing IDEXX to provide options for all segments of the in-house hematology market.

“The customer experience has been extremely positive, which is generating enthusiasm across the marketplace as the awareness of the ProCyte Dx analyzer increases,” said Jon Ayers, IDEXX Chairman and CEO. “The veterinary industry’s reception of the ProCyte Dx analyzer makes this one of the most successful instrument launches in the history of the Company.”

The analyzer’s reliable performance has also been documented in four abstracts published by the American College of Veterinary Internal Medicine (ACVIM) as well as two published abstracts that were presented at the 2010 combined meeting of the European College of Veterinary Internal Medicine (ECVIM), European College of Veterinary Clinical Pathology (ECVCP) and the European Society of Veterinary Clinical Pathology (ESVCP).

The combination of three technologies in the ProCyte Dx analyzer allows it to match or exceed the capabilities of reference laboratory hematology analyzers. Laser flow cytometry is the same technology used in the market-leading IDEXX LaserCyte Hematology Analyzer to deliver an advanced five-part differential for the most accurate white blood cell analysis. In addition, the ProCyte Dx analyzer features two other state-of-the-art technologies: optical fluorescence, the gold standard for classifying reticulocytes and identifying platelets, and laminar flow impedance, which performs the fastest analysis of the size and number of red blood cells.

The ProCyte Dx analyzer's simple load-and-go operation further streamlines technicians' work flow. It requires only 30 µL of EDTA3-treated whole blood and provides up to 24 different veterinary-validated parameters for five distinct species4 (canine, feline, equine, ferret, and bovine). Its two-minute run time complements the speed of the Catalyst Dx Chemistry Analyzer. Now in only eight minutes, veterinarians can run a comprehensive chemistry and hematology diagnostic panel. Both analyzers interface with the IDEXX VetLab Station for integration of all diagnostic results into one easy-to-read printout. Results are automatically recorded and stored in patients' electronic records. The analyzers are supported by IDEXX SmartService Solutions, our most advanced, proactive level of customer care, which connects trained technicians to select IDEXX VetLab instruments through the Internet.

The ProCyte Dx analyzer will be demonstrated at the North American Veterinary Conference (NAVC) in Orlando, Florida, January 15–19, 2011, Booth #2207. More information can also be obtained by visiting or calling IDEXX. In North America, call 1-800-355-2896; in Europe, call 00800 1234 3399.

About IDEXX VetLab In-house Analyzers
IDEXX VetLab veterinary analyzers are highly integrated and the fast results on patients’ blood and urine help veterinarians provide Real-Time Care during the examination visit. Timely answers allow face-to-face discussions about results with clients, aiding pet owner understanding and improving treatment plan compliance. The IDEXX VetLab analyzers’ in-house diagnostic capabilities include clinical chemistry, electrolytes, hematology with an advanced five-part differential and reticulocyte count, endocrinology, blood gas, coagulation, urinalysis and infectious diseases. The IDEXX VetLab Station, the in-house laboratory information management system, integrates results from all the analyzers (including the newly-introduced ProCyte Dx Hematology Analyzer) and SNAP point-of-care tests into a single comprehensive and easy-to-use patient report that facilitates client communication. The information in the IDEXX VetLab Station’s electronic database is stored for easy future reference and historical results trending. In addition, most IDEXX VetLab instruments are supported by IDEXX SmartService Solutions, which delivers proactive service over the Internet.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,800 people and offers products to customers in over 100 countries.

Note Regarding Forward-looking Statements
This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to manufacture complex biologic products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the effects of interruptions to the Company's operations due to natural disasters or system failures. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 (PDF), and quarterly report on Form 10-Q for the quarter ended September 30, 2010 (PDF), in the section captioned "Risk Factors."


IDEXX Laboratories
Robert Barca
Hematology Marketing Director

  1. The validation process has entailed running more than 80,000 samples to date in numerous field trials.
  2. Dr. Rebar has a business relationship with IDEXX pursuant to which he receives compensation from IDEXX from time to time. The views expressed are solely those of Dr. Rebar.
  3. EDTA (ethylenediaminetetraacetic acid) is an organic water-soluble compound used to prevent clotting in blood samples.
  4. The number of reported parameters may vary according to species.